{
    "Rank": 988,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT00216021",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "HOG BRE03-60"
                },
                "Organization": {
                    "OrgFullName": "Hoosier Cancer Research Network",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer",
                "OfficialTitle": "A Phase II Trial of Capecitabine and Oxaliplatin (CAPOX) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE03-60"
            },
            "StatusModule": {
                "StatusVerifiedDate": "December 2015",
                "OverallStatus": "Completed",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "March 2004"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "June 2007",
                    "PrimaryCompletionDateType": "Actual"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "June 2007",
                    "CompletionDateType": "Actual"
                },
                "StudyFirstSubmitDate": "September 9, 2005",
                "StudyFirstSubmitQCDate": "September 14, 2005",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "September 22, 2005",
                    "StudyFirstPostDateType": "Estimate"
                },
                "LastUpdateSubmitDate": "December 8, 2015",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "December 9, 2015",
                    "LastUpdatePostDateType": "Estimate"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Principal Investigator",
                    "ResponsiblePartyInvestigatorFullName": "Kathy Miller, MD",
                    "ResponsiblePartyInvestigatorTitle": "Professor, IU School of Medicine",
                    "ResponsiblePartyInvestigatorAffiliation": "Hoosier Cancer Research Network"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Hoosier Cancer Research Network",
                    "LeadSponsorClass": "OTHER"
                },
                "CollaboratorList": {
                    "Collaborator": [
                        {
                            "CollaboratorName": "Sanofi",
                            "CollaboratorClass": "INDUSTRY"
                        },
                        {
                            "CollaboratorName": "Hoffmann-La Roche",
                            "CollaboratorClass": "INDUSTRY"
                        },
                        {
                            "CollaboratorName": "Walther Cancer Institute",
                            "CollaboratorClass": "OTHER"
                        }
                    ]
                }
            },
            "OversightModule": {
                "OversightHasDMC": "Yes"
            },
            "DescriptionModule": {
                "BriefSummary": "In vitro data suggest synergy between oxaliplatin and 5-FU. The combination of oxaliplatin with 5-fluorouracil produced objective response rates ranging from 27-34% in two studies of patients with prior chemotherapy. Capecitabine was designed as an orally administered, tumor selective fluoropyrimidine, preferentially converted to 5-FU at the tumor site by the higher levels of pyrimidine nucleoside phosphorylase (PyNPase) in tumor tissues compared to normal tissues. The end result is higher concentrations of 5-fluorouracil in tumor relative to surrounding normal tissue. This trial will investigate the activity of this novel capecitabine/oxaliplatin (CAPOX) combination in patients with advanced disease. In addition, an exploratory analysis will correlate response with thymidine synthase and thymidine phosphorylase expression in primary tumor samples.",
                "DetailedDescription": "OUTLINE: This is a multi-center study.\n\nCAPOX (21 day cycle):\n\nCapecitabine 825 mg/m2 orally twice daily Days 1-14.\nOxaliplatin 100 mg/m2 intravenously Day 1\n\nPatients may continue combination therapy until progression or toxicity intervenes. Patients who discontinue either agent due to toxicity may, at the investigators discretion, continue therapy with the remaining single agent on study.\n\nECOG performance status 0 or 1\n\nHematopoietic:\u00b7\n\nANC > 1,200/mm3\u00b7\nPlatelets > 100,000/mm3\n\nHepatic:\u00b7\n\nTotal bilirubin < 1.5 x ULN\u00b7\nAST < 2 x ULN (up to 5 x ULN in patients with known liver involvement)\n\nRenal:\u00b7\n\nSerum creatinine < 1.5 x ULN and estimated creatinine clearance >50ml/min as calculated with Cockroft-Gault equation\n\nCardiovascular:\u00b7\n\nNo clinically significant cardiac disease (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias not well controlled with medication) or myocardial infarction within the last 12 months."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Metastatic Breast Cancer"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "Breast Cancer"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Phase 2"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "N/A",
                    "DesignInterventionModel": "Single Group Assignment",
                    "DesignPrimaryPurpose": "Treatment",
                    "DesignMaskingInfo": {
                        "DesignMasking": "None (Open Label)"
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "25",
                    "EnrollmentType": "Actual"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "Single Group Assignment",
                            "ArmGroupType": "Experimental",
                            "ArmGroupDescription": "Capecitabine + Oxaliplatin",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Drug: Capecitabine",
                                    "Drug: Oxaliplatin"
                                ]
                            }
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "Capecitabine",
                            "InterventionDescription": "Capecitabine 825 mg/m2 po bid, days 1-14",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Single Group Assignment"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "Oxaliplatin",
                            "InterventionDescription": "Oxaliplatin 100 mg/m2 IV, day 1",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Single Group Assignment"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "- To determine the objective response rate (CR+PR) of capecitabine and oxaliplatin (CAPOX) in patients with metastatic breast cancer.",
                            "PrimaryOutcomeTimeFrame": "36 months"
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "To measure time to progression \u00b7",
                            "SecondaryOutcomeTimeFrame": "36 months"
                        },
                        {
                            "SecondaryOutcomeMeasure": "To determine rate of clinical benefit response (CR + PR + SD > 6 months). \u00b7",
                            "SecondaryOutcomeTimeFrame": "36 months"
                        },
                        {
                            "SecondaryOutcomeMeasure": "To determine toxicity rate of CAPOX in this patient population.\u00b7",
                            "SecondaryOutcomeTimeFrame": "36 months"
                        },
                        {
                            "SecondaryOutcomeMeasure": "To explore potential correlations between thymidine synthase (TS), thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) expression in the primary tumor with response.",
                            "SecondaryOutcomeTimeFrame": "36 months"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "Inclusion Criteria:\n\nHistologic or cytologic diagnosis of breast cancer with evidence of (1) unresectable, locally recurrent, or (2) metastatic disease.\u00b7\nPatients with HER2 positive (3+ overexpression by IHC or gene amplification by FISH) are eligible only if they have had prior trastuzumab therapy.\u00b7\nAt least one measurable lesion as defined by the RECIST.\nPrior radiation therapy is allowed as long as the irradiated area is not the only source of measurable disease.\n\nExclusion Criteria:\n\nNo prior therapy with capecitabine or oxaliplatin in any setting\nNo prior therapy with other platinum compounds\u00b7\nNo other forms of cancer therapy including radiation, chemotherapy and hormonal therapy within 21 days prior to beginning protocol therapy.\u00b7\nNo prior unanticipated severe reaction to fluoropyrimidine therapy, or known sensitivity to 5-fluorouracil.\u00b7\nNo prior fluoropyrimidine therapy for metastatic disease is allowed. Prior adjuvant fluoropyrimidine therapy is allowed if completed > 12 months from study entry.\u00b7\nMaximum of one prior chemotherapy regimen for unresectable, locally recurrent or metastatic disease\u00b7\nNo symptomatic brain metastasis. \u00b7\nNo evidence of serious concomitant systemic disorders incompatible with the study \u00b7\nNo peripheral neuropathy \u00b7\nNo major surgery within 28 days prior to beginning protocol therapy.\u00b7\nNegative pregnancy test\u00b7\nNo female patients currently breastfeeding\u00b7\nNo malabsorption syndrome\u00b7\nNo evidence of serious concomitant systemic disorders incompatible with the study\u00b7\nPatients must not be treated with any of the following while on protocol therapy or within 28 days prior to beginning protocol therapy: sorivudine, brivudine, cimetidine, allopurinol.",
                "HealthyVolunteers": "No",
                "Gender": "Female",
                "MinimumAge": "18 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Kathy Miller, M.D.",
                            "OverallOfficialAffiliation": "Hoosier Oncology Group, LLC",
                            "OverallOfficialRole": "Study Chair"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "Helen F. Graham Cancer Center",
                            "LocationCity": "Newark",
                            "LocationState": "Delaware",
                            "LocationZip": "19713",
                            "LocationCountry": "United States"
                        },
                        {
                            "LocationFacility": "Medical & Surgical Specialists, LLC",
                            "LocationCity": "Galesburg",
                            "LocationState": "Illinois",
                            "LocationZip": "61401",
                            "LocationCountry": "United States"
                        },
                        {
                            "LocationFacility": "Elkhart Clinic",
                            "LocationCity": "Elkhart",
                            "LocationState": "Indiana",
                            "LocationZip": "46515",
                            "LocationCountry": "United States"
                        },
                        {
                            "LocationFacility": "Oncology Hematology Associates of SW Indiana",
                            "LocationCity": "Evansville",
                            "LocationState": "Indiana",
                            "LocationZip": "47714",
                            "LocationCountry": "United States"
                        },
                        {
                            "LocationFacility": "Indiana University Cancer Center",
                            "LocationCity": "Indianapolis",
                            "LocationState": "Indiana",
                            "LocationZip": "46202",
                            "LocationCountry": "United States"
                        },
                        {
                            "LocationFacility": "Quality Cancer Center (MCGOP)",
                            "LocationCity": "Indianapolis",
                            "LocationState": "Indiana",
                            "LocationZip": "46202",
                            "LocationCountry": "United States"
                        },
                        {
                            "LocationFacility": "Community Regional Cancer Center",
                            "LocationCity": "Indianapolis",
                            "LocationState": "Indiana",
                            "LocationZip": "46256",
                            "LocationCountry": "United States"
                        },
                        {
                            "LocationFacility": "Medical Consultants, P.C.",
                            "LocationCity": "Muncie",
                            "LocationState": "Indiana",
                            "LocationZip": "47303",
                            "LocationCountry": "United States"
                        },
                        {
                            "LocationFacility": "Center for Cancer Care, Inc., P.C.",
                            "LocationCity": "New Albany",
                            "LocationState": "Indiana",
                            "LocationZip": "47150",
                            "LocationCountry": "United States"
                        },
                        {
                            "LocationFacility": "Northern Indiana Cancer Research Consortium",
                            "LocationCity": "South Bend",
                            "LocationState": "Indiana",
                            "LocationZip": "46601",
                            "LocationCountry": "United States"
                        },
                        {
                            "LocationFacility": "AP&S Clinic",
                            "LocationCity": "Terre Haute",
                            "LocationState": "Indiana",
                            "LocationZip": "47804",
                            "LocationCountry": "United States"
                        }
                    ]
                }
            },
            "ReferencesModule": {
                "SeeAlsoLinkList": {
                    "SeeAlsoLink": [
                        {
                            "SeeAlsoLinkLabel": "Hoosier Oncology Group Home Page",
                            "SeeAlsoLinkURL": "http://www.hoosieroncologygroup.org"
                        }
                    ]
                }
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000001943",
                            "ConditionMeshTerm": "Breast Neoplasms"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000001941",
                            "ConditionAncestorTerm": "Breast Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000012871",
                            "ConditionAncestorTerm": "Skin Diseases"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M4910",
                            "ConditionBrowseLeafName": "Breast Neoplasms",
                            "ConditionBrowseLeafAsFound": "Breast Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M4908",
                            "ConditionBrowseLeafName": "Breast Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M15364",
                            "ConditionBrowseLeafName": "Skin Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC17",
                            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        }
                    ]
                }
            },
            "InterventionBrowseModule": {
                "InterventionMeshList": {
                    "InterventionMesh": [
                        {
                            "InterventionMeshId": "D000069287",
                            "InterventionMeshTerm": "Capecitabine"
                        },
                        {
                            "InterventionMeshId": "D000077150",
                            "InterventionMeshTerm": "Oxaliplatin"
                        }
                    ]
                },
                "InterventionAncestorList": {
                    "InterventionAncestor": [
                        {
                            "InterventionAncestorId": "D000000964",
                            "InterventionAncestorTerm": "Antimetabolites, Antineoplastic"
                        },
                        {
                            "InterventionAncestorId": "D000000963",
                            "InterventionAncestorTerm": "Antimetabolites"
                        },
                        {
                            "InterventionAncestorId": "D000045504",
                            "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
                        },
                        {
                            "InterventionAncestorId": "D000000970",
                            "InterventionAncestorTerm": "Antineoplastic Agents"
                        }
                    ]
                },
                "InterventionBrowseLeafList": {
                    "InterventionBrowseLeaf": [
                        {
                            "InterventionBrowseLeafId": "M1674",
                            "InterventionBrowseLeafName": "Oxaliplatin",
                            "InterventionBrowseLeafAsFound": "Function",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M377",
                            "InterventionBrowseLeafName": "Capecitabine",
                            "InterventionBrowseLeafAsFound": "Ultrasound",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M3971",
                            "InterventionBrowseLeafName": "Antimetabolites",
                            "InterventionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "InterventionBrowseBranchList": {
                    "InterventionBrowseBranch": [
                        {
                            "InterventionBrowseBranchAbbrev": "ANeo",
                            "InterventionBrowseBranchName": "Antineoplastic Agents"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "All",
                            "InterventionBrowseBranchName": "All Drugs and Chemicals"
                        }
                    ]
                }
            }
        }
    }
}